InsidersTradesSigma
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Discover the detailed record of transactions filed by Chan Mitchell. Director active across 2 companies, notably Avalo Therapeutics, Inc.. Aggregated, 5 reports have been recorded. Activity tracked since 16 September 2024. The latest transaction was disclosed on 6 January 2026 (Attribution). Regulator: SEC (Form 4). The full history is free.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 of 5 declarations
Chan Mitchell is Chief Financial Officer at REGENXBIO Inc. and Director at Avalo Therapeutics, Inc. This person has 4 filings in total, and across the 4 sampled filings from 2024-09-18 to 2026-03-31, the most common transaction type is option exercise.